Research group and committee session
| RS1 Research group on diabetic vascular cell biology session : Cardiovascular ketone signaling LIVE Channel A |
14:00~16:00 / Thursday 7 October Chairman:Kyu Jeung Ahn, Changhee Jung |
Overview | |||
|---|---|---|---|---|---|
| After the cardiovascular outcome trials using SGLT2 inhibitor have proved strong evidence of its cardio-renal benefit, growing attention has been paid to its underlying mechanisms. Among the suggested plausible mechanisms, the altered metabolism of the ketone body, which is known to be increased by SGLT2 inhibitor treatment, has been proposed as one of the potential contributors to its benefit, especially for heart failure. In this session, four speakers will deliver talks about the role of the ketone body in heart metabolism and present its potential as a new therapeutic candidate for cardiovascular diseases. | |||||
|
RS1-1Are ketone bodies really important metabolic fuel for the heart? | ||||
|
RS1-2Ketone metabolism in the failing and nonfailing human heart | ||||
|
RS1-3Therapeutic potential of ketone bodies for patients with CVD | ||||
|
RS1-4SGLT2 inhibition-derived ketones protects diabetic cardiovascular disease | ||||
|
|||||
| RS2 Research group on diabetic neuropathy : Diabetic peripheral neuropathy - present and future strategies LIVE Channel B |
14:00~16:00 / Thursday 7 October Chairman:Tae sun Park, Ji Hyun Lee |
Overview | ||
|---|---|---|---|---|
| This session entitled ‘Diabetic Peripheral Neuropathy—Present and Future Strategies’ is a translational session and is designed to provide a place for clinicians to understand the diagnosis, proper management and emerging biomarkers for diabetic peripheral neuropathy(DPN) in people with diabetes. DPN is diagnosed too late where incipient disease is detected early enabling timely treatment. In this session, we will focus on the small fibers of several novel diagnostic techniques for the early detection of DPN. We'll look at the multimodal treatment including the individual risk profile, pathogenetic treatment and pain management using pharmacotherapy as well as non-pharmacological options, and emerging biomarkers and tools for DPN. There will be 3 speakers presenting and a 2-panelist discussion. This session will provide a better understanding of the diagnosis and management of DPN. | ||||
|
RS2-1Diabetic peripheral neuropathy: a focus on small fibers | |||
|
RS2-2Emerging biomarkers and tools for diabetic peripheral neuropathy | |||
|
RS2-3Current concepts in the management of diabetic neuropathy | |||
|
||||
| RS3 Research group on diabetic nephropathy : New promising therapeutic targets on diabetic kidney disease LIVE Channel C |
14:00~16:00 / Thursday 7 October Chairman:Hunjoo Ha, Nan Hee Kim |
Overview | ||||
|---|---|---|---|---|---|---|
| Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease (ESKD). Inhibitors of the renin-angiotensin system could delay progression to ESKD, but it is not enough to prevent it. This session entitled “New promising therapeutic targets on diabetic kidney disease” is a research session. Four eminent researchers will discuss new therapeutic targets on DKD with their data. Please join this session to share the latest knowledge. | ||||||
|
RS3-1NOX5 in diabetic kidney disease | |||||
|
RS3-2The role of VSIG4 in diabetic nephropathy | |||||
|
RS3-3The nuclear receptor ESRRA protects from kidney disease by coupling metabolism and differentiation | |||||
|
RS3-4Renal ketone body metabolism as a promising therapeutic target for DKD | |||||
|
||||||
| RS4 Research group on fatty liver disease : Recent updates on pathogenesis and treatment of non-alcoholic fatty liver disease LIVE Channel D |
14:00~16:00 / Thursday 7 October Chairman:Won Young Lee, Rhee Eun-Jung |
Overview | |||
|---|---|---|---|---|---|
| This session is organized by Fatty Liver Research Group to introduce recent updates on concepts, pathogenesis and management of non-alcoholic fatty liver disease (NAFLD). In this session, a novel concept of MAFLD (metabolic dysfunction-associated fatty liver disease) in relation to NAFLD will be discussed and all recently revised guidelines for the management of NAFLD by the Korean Association for the Study of Liver will be introduced. In addition, an interesting topic on mitochondrial unfoled protein and myokines as the pathogenic mechanism for fatty liver will be presented. Lastly, recent updates on anti-diabetic medications as a promising treatment strategy for NAFLD/non-alcoholic steatohepatitis will be discussed. | |||||
|
RS4-12021 KASL clinical practice guidelines: management of nonalcoholic fatty liver disease | ||||
|
RS4-2MAFLD: a new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement | ||||
|
RS4-3Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease | ||||
|
RS4-4Implications of mitochondrial unfolded protein response and mitokines: a perspective on fatty liver diseases | ||||
|
|||||
| CS1 Committee of clinical practice guideline: Clinical inertia in KDA guidelines-recommended strategies among patients with diabetes and cardiovascular comorbidities or who need injectable therapy LIVE Channel A |
16:00~17:30 / Friday 8 October Chairman:Sungdae Moon, Seung-Hyun Ko |
Overview | ||||
|---|---|---|---|---|---|---|
| Clinical inertia is defined as the failure of healthcare providers to initiate or intensify therapy when indicated. Despite the many evidence and clear recommendations of 2021 KDA Clinical Practice Guidelines, it seems that sodium–glucose cotransporter 2 (SGLT2) inhibitors or glucagon-like peptide 1 receptor agonists (GLP-1RAs) among the patients with type 2 diabetes mellitus (T2DM) with cardiovascular (CV) comorbidities, or intensification with injectable therapy for patients are not meeting treatment goals and are still underutilized when indicated in real world practice. In this session, we will review prescribing patterns of SGLT2 inhibitors or GLP-1RAs among the patients with type 2 diabetes mellitus (T2DM) with heart failure or established cardiovascular disease. And to find out the primary reasons of clinical inertia to timely insulin intensification, we conducted a survey of diabetes healthcare professionals and assessed factors that influence clinical decision-making regarding insulin initiation in T2D. |
||||||
|
CS1-1Real-world treatment patterns according to KDA guideline in patients with type 2 diabetes and established ASCVD: based on multicenter data | |||||
|
CS1-2Real-world treatment patterns according to KDA guideline in patients with type 2 diabetes and established ASCVD: based on KNHIS data | |||||
|
CS1-3Clinical inertia in Korean people with type 2 diabetes | |||||
|
||||||
| CS2 Committee of the health insurance and legislation: Reinforcement of insurance coverage for diabetic patients LIVE Channel B |
16:00~17:30 / Friday 8 October Chairman:Tae sun Park, Chong Hwa Kim |
Overview | ||||
|---|---|---|---|---|---|---|
| Diabetes is a patient-centered self-controled disease based on lifestyle education, so a health care system with a focus on prevention should be established as a national policy. In this session, we will look at the status of the type 1 diabetes home medical pilot project and suggest a policy for strengthening medical coverage including a continuous glucose monitoring system and a variety of anti-hyperglycemic agents. This session will provide an excellent venue for the exchange of opinions between the government and academic societies to improve the treatment progress of Korean diabetic patients. | ||||||
|
CS2-1Status of telemedicine pilot project for type 1 diabetics | |||||
|
CS2-2The summary & issue of health insurance for continuous glucose monitoring system in Korea | |||||
|
CS2-3The summary & issue of health insurance for treatment of diabetes | |||||
|
||||||
| CS3 Diabetes and metabolism journal session: Best papers at DMJ 2020 LIVE Channel C |
16:00~17:30 / Friday 8 October Chairman:In-Kyung Jeong, Jung Hyun Noh |
Overview |
|---|---|---|
| This session entitled ‘DMJ 2020 best paper of the year ' is designed to provide a platform for clinicians and basic researchers. The 'Diabetes and metabolism Journal (DMJ)’ which publishes original research related to diabetes, is the official journal of the Korean Diabetes Association indexed in SCIE, Medline, PubMed, and SCOPUS. In this session, the most outstanding articles in the DMJ in 2020 selected by The Committee of Publication of KDA will be presented with their excellent achievements. | ||
|
CS3-1Glucagon-like peptide-1 receptor agonist differentially affects brain activation in response to visual food cues in lean and obese individuals with type 2 diabetes mellitus | |
|
CS3-2The clinical characteristics and outcomes of patients with moderate-to-severe coronavirus disease 2019 infection and diabetes in Daegu, South Korea | |
|
CS3-3Independent impact of diabetes on the severity of coronavirus disease 2019 in 5,307 patients in South Korea: A nationwide cohort study | |
|
CS3-4Inhibition of ceramide accumulation in podocytes by myriocin prevents diabetic nephropathy | |
|
CS3-5Associations among obesity degree, glycemic status, and risk of heart failure in 9,720,220 Korean adults | |
|
CS3-6An electronic health record-integrated computerized intravenous insulin infusion protocol: clinical outcomes and in silico adjustment | |
| CS4 Committee of international liaison: The 100th Anniversary of Insulin Discovery LIVE Channel D |
16:00~17:30 / Friday 8 October Chairman:Sin Gon Kim, Sung Hee Choi |
Overview |
|---|---|---|
| The discovery of insulin is arguably one of the most important in the history of medicine and one of the most dramatic examples of rapid translation of a discovery in basic science into a benefit for patients. In celebration of insulin's 100th anniversary, we prepared for a session in which the past and current status of insulin treatment in various regions (Europe, Korea, Japan and Taiwan) will be discussed. This session will be a great chance for us to share our experiences in the treatment of diabetes using insulin. | ||
|
CS4-1Current situation of insulin therapy in Korea: to advance or to decline? | |
|
CS4-2Insulin therapy in Denmark | |
|
CS4-3Current status of insulin treatment in Japan | |
|
CS4-4The experience of insulin in Taiwan | |
